Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BY101921 combined with a PD-1/VEGF bispecific antibody in malignant solid tumors
CTR20263983Phase 2Active
- Sponsor
- Combi-Blocks
- Start
- Nov 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BY101921 and anti-PD-1/VEGF bispecific antibodies in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC) and 3 more (4 arms), sponsored by Combi-Blocks. Primary endpoints: Safety and tolerability, Objective response rate and 7 more. Started Nov 2026; status: active.
02
Drugs
BY101921anti-PD-1/VEGF bispecific antibodies
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20263983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263983.